Abstract Library

#2151 Therapeutic Efficacy of Platinum/Etoposide Regimens in the Treatment of Advanced Poor Differentiated Neuroendocrine Carcinomas of the Lung: A Retrospective Analysis

Introduction: Advanced neuroendocrine carcinomas (NEC) of the lung are associated with a dismal prognosis and are commonly treated with platinum/etoposide (P/E) regimens. However, few studies evaluated their impact in lung NEC and it is still unclear whether the outcome of such patients (pts) has been improved over the past years (yrs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Giuffrida D

Authors: Giuffrida D, Chillari F, Blanco G, Russo A, Franchina T,

Keywords: neuroendocrine carcinoma, lung, platinum-etoposide, LCNEC, SCLC, chemotherapy,

#1819 Initial Experience of a Novel Endoscopic Full Thickness Resection Device (FTRD) for the Treatment of Rectal Neuroendocrine Tumours

Introduction: Standard endoscopic resection of rectal NETs is often associated with histological incomplete excision due to submucosal position within the bowel. Endoscopic full thickness resection may allow early definitive management.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Fong M, Ramsey E, Boger P, Ellis R, Knight J,

Keywords: endoscopic full thickness resection, rectal NET,

#1410 Predictive Factors for Survival in Patients with Advanced Small Bowel Neuroendocrine Tumours

Introduction: Tumour grade and hepatic metastases are negative prognostic factors for advanced small bowel neuroendocrine tumours (SBNETs), but data assessing other prognosticators at diagnosis (Dx) are lacking.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: TOUMPANAKIS C

Authors: Toumpanakis C, Vlachou E, Ramakrishnan S, Phillips E, Tuck A,

Keywords: small bowel NETs, prognosis,

#1408 Epidemiological Factors at Diagnosis in a Large Cohort of Patients with Small Bowel Neurondocrine Tumours

Introduction: The incidence of small bowel Neuroendocrine Tumours (SBNETs) has been increasing. Despite previous reports, epidemiological data regarding several clinical factors are limited.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: TOUMPANAKIS C

Authors: Toumpanakis C, Vlachou E, Wilkins D, Tuck A, Phillips E,

Keywords: Small bowel NETs, epidemiology, diagnosis,

#932 Hematological Toxicity of Combined Lutetium-177 Octreotate Radiopeptide-Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors Followed Long-Term

Introduction: Combination radiopeptide therapy (PRRT) with radiosensitizing chemotherapy of gastroenteropancreatic neuroendocrine tumors (GEP NETs) may improve efficacy, but has the potential to increase myelotoxicity.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Kesavan M

Authors: Kesavan M, Claringbold P, Turner J,

Keywords: PRRT, GEP-NET,